Trials / Completed
CompletedNCT03732560
A Comparison of Nivolumab-based Treatments in a Real-world PD-L1 Positive Metastatic Melanoma Population in the US
A Retrospective Observational Study Comparing Nivolumab + Ipilimumab Combination vs. Nivolumab Monotherapy as First Line Treatment of Metastatic PD-L1 Positive Melanoma in the US
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 600 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this study is to describe patient characteristics, treatment outcomes and adverse events for patients with metastatic melanoma testing positive for PD-L1 expression treated first line (1L) with either nivolumab and ipilimumab in combination (NIVO + IPI) or nivolumab (NIVO) monotherapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Non-Interventional | Non-Interventional |
Timeline
- Start date
- 2018-07-31
- Primary completion
- 2021-03-25
- Completion
- 2021-03-25
- First posted
- 2018-11-06
- Last updated
- 2022-12-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03732560. Inclusion in this directory is not an endorsement.